Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU‐related toxicity
- 1 March 2007
- journal article
- case report
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 64 (2), 237-240
- https://doi.org/10.1111/j.1365-2125.2007.02869.x
Abstract
To examine retrospectively the relationship between DPD phenotype/genotype and the intensity of 5FU toxicity. One hundred and thirty-one case-reports (81 women, 50 men) with 5FU-related toxicity were analyzed. The lower the DPD activity (10-504 pmol min(-1) mg(-1)), the higher the toxicity grade was scored (P < 0.01). Toxicity-related deaths occurred in nine patients (eight women) who significantly expressed lower DPD activity than other patients. Two of the deceased patients had normal DPD activity. The IVS14+1G>A mutation, analyzed in 93 patients, was detected in two patients (nonlethal toxicity). The IVS14+1G>A mutation may not help prevent toxicity and patients with normal DPD activity may develop life-threatening 5FU toxicity.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacogenetics of Capecitabine in Advanced Breast Cancer PatientsClinical Cancer Research, 2006
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal Of Cancer, 2004
- High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.Published by Rockefeller University Press ,2002
- Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.2001
- Known variant DPYD alleles do not explain DPD deficiency in cancer patientsPharmacogenetics, 2000
- Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU DosageJournal of Clinical Oncology, 1999
- Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicityBritish Journal of Cancer, 1999
- Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer.Journal of Clinical Oncology, 1998
- Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.British Journal of Cancer, 1998
- RELATIONSHIP BETWEEN DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY AND PLASMA 5-FLUOROURACIL LEVELS WITH EVIDENCE FOR CIRCADIAN VARIATION OF ENZYME-ACTIVITY AND PLASMA DRUG LEVELS IN CANCER-PATIENTS RECEIVING 5-FLUOROURACIL BY PROTRACTED CONTINUOUS INFUSION1990